Urology – Medxy AI

Testosterone and Weight Loss: Decoding the Link Between Sex Hormones and Cardiovascular Risk in Men with Type 2 Diabetes

By MedXY 03/09/2026

A longitudinal analysis of the Look AHEAD trial demonstrates that baseline testosterone and weight loss-induced changes in SHBG significantly modulate cardiovascular risk in men with type 2 diabetes, highlighting the critical role of hormonal health in metabolic management.

Dermatology news Urology

Navigating Scrotal Health: A Comprehensive Guide to Lymphedema and Excessive Sweating

By MedXY 03/08/2026

This article provides an in-depth exploration of scrotal lymphedema and hyperhidrosis, detailing their physiological causes, clinical symptoms, and the latest management strategies for both patients and healthcare providers.

news Oncology Urology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY 03/06/2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standards for recurrent prostate cancer.

news Oncology Urology

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY 03/04/2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for patients ineligible for cisplatin-based chemotherapy.

Clinical Updates Family Medicine & Nutrition news Urology

Vitamin D Co-administration as a Protective Strategy Against Obesity-Induced Male Reproductive Dysfunction: Mechanistic Insights and Clinical Implications

By MedXY 03/02/2026

This review synthesizes recent evidence on how Vitamin D mitigates high-fat diet-induced testicular and sperm dysfunction, focusing on hormonal recovery, blood-testis barrier stabilization, and mitochondrial protection.

Clinical Updates news Oncology Radiology Urology

Risk Stratification in PSMA PET-Staged Oligorecurrent Prostate Cancer: Clinical Synthesis of the PORTAL Nomogram and Metastasis-Directed Therapy

By MedXY 02/26/2026

This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.

AI news Urology

Telesurgery Breaks the Distance Barrier: Landmark RCT Confirms Non-Inferiority to Local Robotic Urology

By MedXY 02/23/2026

A multicentre randomized controlled trial demonstrates that robotic telesurgery over distances up to 2800 km is non-inferior to local surgery for urological procedures, maintaining high success rates, low latency, and equivalent safety profiles.

news Oncology Urology

Perioperative Enfortumab Vedotin and Pembrolizumab: A Practice-Changing Advance for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

By MedXY 02/22/2026

The Phase 3 KEYNOTE-905/EV-303 trial demonstrates that perioperative enfortumab vedotin plus pembrolizumab significantly improves event-free survival (HR 0.40) and overall survival (HR 0.50) compared to surgery alone in cisplatin-ineligible patients with muscle-invasive bladder cancer.

news Oncology Urology

Salvage Focal Therapy vs. Radical Prostatectomy: Comparable 10-Year Survival with Dramatically Reduced Morbidity

By MedXY 02/20/2026

A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications for patients with localized radiorecurrent prostate cancer.

news Oncology Urology

Metastasis-Directed Therapy Delivers Clear Progression Benefits in Oligometastatic Prostate Cancer: The WOLVERINE IPD Meta-Analysis

By MedXY 02/18/2026

The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence for a paradigm shift in clinical management.

news Oncology Urology

Docetaxel Rechallenge vs Cabazitaxel: Choosing the Right Taxane Sequence in Metastatic Castration-Resistant Prostate Cancer

By MedXY 02/09/2026

A retrospective cohort study of 669 veterans suggests that docetaxel rechallenge provides a significant survival benefit compared to cabazitaxel for patients with metastatic castration-resistant prostate cancer who previously responded to docetaxel without disease progression.

news Oncology Urology

Low Baseline PSA Predicts Exceptional Long-Term Safety: A 20-Year Paradigm Shift in Prostate Cancer Screening

By MedXY 02/09/2026

A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals for low-risk individuals.

news Urology

PGT-A for Severe Male Infertility: Reducing Pregnancy Loss Without Boosting Live Birth Rates

By MedXY 01/22/2026

A multicentre RCT published in the BMJ demonstrates that while PGT-A does not increase cumulative live birth rates for couples with severe male infertility, it significantly reduces the risk of pregnancy loss, providing a nuanced framework for clinical counseling.

news Oncology Urology

Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial

By MedXY 01/14/2026

The Phase III ALBAN trial found that adding atezolizumab to BCG therapy did not improve event-free survival in BCG-naive high-risk non-muscle-invasive bladder cancer, highlighting the complexity of immune checkpoint inhibitor synergy in this setting.

news Oncology Urology

Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial

By MedXY 01/13/2026

The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.

news Oncology Urology

Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/13/2026

This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary treatment standards.

news Oncology Urology

Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/12/2026

A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MSI as a viable alternative for patient selection.

news Oncology Urology

MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer

By MedXY 01/12/2026

A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for patient selection when tissue is limited.

news Oncology Urology

AHR Inhibition with IK-175: A New Frontier in Overcoming Checkpoint Resistance in Urothelial Carcinoma

By MedXY 01/11/2026

This Phase 1/1b study demonstrates that IK-175, an oral AHR inhibitor, is safe and clinically active in PD-1-refractory urothelial carcinoma, showing target engagement and preliminary efficacy both as monotherapy and in combination with nivolumab.

news Oncology Urology

The Evolving Paradigm in High-Risk NMIBC: Critical Synthesis of Checkpoint Inhibitors and BCG Combination Therapy

By MedXY 01/10/2026

A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy suggest a need for cautious, individualized clinical adoption.